Hims & Hers Health shares fell about 5% in after-hours trading after reports that the Federal Trade Commission has been investigating the telehealth company’s advertising and cancellation practices for more than a year. The regulatory hit adds to a bruising summer for HIMS, which plunged 32% in June when Novo Nordisk cut ties and accused the company of deceptive marketing around compounded versions of its weight-loss drug Wegovy. Analysts have warned that as Novo Nordisk and Eli Lilly scale up supply of their branded GLP-1 therapies, Hims’ compounded offerings could lose relevance. The company has not commented on the latest probe.
Bloomberg reported the FTC inquiry late Wednesday, citing concerns with how Hims markets products and how consumers can cancel subscriptions. The disclosure of a year-long investigation changes the time horizon of the regulatory risk. It suggests the agency has already spent months gathering documents and interviewing parties, raising the chance of formal action or a settlement that could force changes to how Hims acquires and retains customers. The stock reaction was swift. A 5% after-hours drop implies investors are recalibrating for fines, operational constraints, or both. Telehealth peers have faced similar scrutiny over marketing claims and negative-option subscription rules. The FTC has also been active in policing cancellation flows that make it hard to turn off recurring charges. For a subscription-heavy model like Hims, even modest friction added by regulators can dent growth math, increase churn, and push up customer acquisition costs.
June’s break with Novo Nordisk remains central to the bear case. Novo Nordisk (NVO) ended the relationship and alleged Hims misled consumers and sold compounded versions of Wegovy. The move erased nearly a third of HIMS’ market value in a day and spotlighted Hims’ exposure to weight-loss demand it cannot fulfill with branded inventory. Compounding pharmacies stepped in during shortages, but the optics around compounded semaglutide have been fraught, with legal and regulatory nuances that most consumers do not parse. The reputational spillover has lasted. The FTC’s focus on advertising practices can easily touch on claims around weight-loss efficacy, safety, and branding, even if the company couches its programs as physician-directed care. Investors will connect the dots between Novo’s accusations and the FTC’s mandate, raising questions about whether tweaks to marketing copy are sufficient or whether deeper structural changes are coming for how Hims sells, bundles, and renews these services.
A second front is opening as Big Pharma ramps production. Bank of America analysts have warned that Hims’ dependence on compounded GLP-1 products could become a liability once Novo Nordisk and Eli Lilly (LLY) meet demand for their branded drugs. If supply constraints ease, the rationale for compounded alternatives fades, and regulators typically tighten tolerance for compounding once a shortage is resolved. That could remove a meaningful growth lever just as Hims faces pressure to revise ads and subscription flows. The risk is not just lost revenue; it is a change in mix that could lower margins if Hims must lean more on lower-ticket categories to offset a slowdown in weight-loss. Meanwhile, broader investor enthusiasm for GLP-1 exposure has rewarded rights holders and well-positioned distributors, not intermediaries caught in gray zones. If the FTC probe forces conservative claims and provides clarity on cancellation, the marketing advantage that fueled Hims’ breakout in weight-loss could compress at the same moment that branded competition becomes more available.
The FTC typically seeks a blend of monetary and behavioral remedies in cases involving advertising and negative-option subscriptions. That can include consumer refunds, disgorgement, civil penalties, and consent orders that mandate clear disclosures, easy-to-use click-to-cancel mechanisms, and stricter substantiation for health claims. For Hims, any consent decree would likely reach beyond a single product page. It could reshape the customer journey across categories, from offer framing and testimonial usage to auto-renew prompts and upsell tactics. That matters for unit economics. If cancellation becomes faster and clearer, churn tends to rise. If claims are narrowed, ad efficiency falls and acquisition costs climb. In the near term, those mechanics can hit revenue growth and marketing ROI, and the market is already discounting future profitability to reflect that scenario. The company can redesign flows to comply and retain more users, but it is hard to avoid a growth pause while rebuilding the funnel under regulatory supervision.
Telehealth has always sold speed and simplicity. The regulatory environment is catching up. Hims’ pitch—direct access, convenient care, subscription refills—works when regulators accept that marketing and retention reflect best practices. An FTC probe of this length signals concerns about whether those practices crossed lines. For management, the task now is to demonstrate that core demand remains intact even if advertising is toned down and cancellations get easier. That means proving brand equity and clinical outcomes can carry more of the load than optimization tricks. It also means showing that non-GLP-1 categories, including hair loss, dermatology, and sexual health, can pick up slack if weight-loss momentum slows. Investors will be watching whether the company can pivot marketing spend into channels and messages that pass regulatory muster without losing conversion.
The first tell will be whether Hims preemptively adjusts marketing assets and cancellation flows before the FTC acts. Fast, visible changes often signal a negotiated path to a consent order and can limit financial damage. Next, clarity on GLP-1 sourcing is critical. Any progress in securing branded supply or a compliant alternative would ease the Novo Nordisk overhang. On the financial side, watch for commentary on churn, lifetime value, and acquisition costs in the next update. If those metrics deteriorate at the same time that revenue mix shifts away from compounded semaglutide, valuation support weakens. Finally, look for signals from Novo Nordisk and Eli Lilly about supply timelines; the faster those stabilize, the sooner the compounding window closes across the sector.
Investor sentiment has shifted from enthusiasm to caution, and that alone can raise costs. Performance marketing works best when equity markets reward growth at all costs. With a regulatory cloud overhead and the GLP-1 bull narrative moving upstream to drugmakers, Hims may have to spend more to stand still in the near term. If the company can use the next few quarters to clean up practices, cement a compliant weight-loss offering, and show stable retention, the stock could re-rate from crisis pricing. If not, the combination of higher churn, softer ad performance, and a shrinking compounded market will push estimates lower.
A 5% after-hours drop is not the worst case for a company staring at a year-long FTC probe and a critical partner dispute in the rearview. But markets tend to price the path, not the point-in-time. The path ahead includes potential fines, operational changes to the core subscription engine, and a crowded, better-supplied GLP-1 landscape that could blunt one of Hims’ biggest growth drivers. With HIMS already on the defensive, the burden shifts to management to show it can navigate regulatory demands and still scale profitably. Until that evidence arrives, the multiple will likely reflect an overhang that won’t lift quickly.
